UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 5, 2016

 

Spotlight Innovation Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

000-52542

98 0518266

(State or other jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

6750 Western Parkway, Suite 200-226 West Des Moines, Iowa

 

50266

(Address of principal executive offices)

 

(Zip Code)

 

Registrant's telephone number, including area code: (515) 274 9087

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8 K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a 12 under the Exchange Act (17 CFR 240.14a 12)

 

¨ Pre commencement communications pursuant to Rule 14d 2(b) under the Exchange Act (17 CFR 240.14d 2(b))

 

¨ Pre commencement communications pursuant to Rule 13e 4(c) under the Exchange Act (17 CFR 240.13e 4(c))

  

 

 
 
 

Item 1.01 Entry into a Material Definitive Agreement.

 

On December 5, 2016, Spotlight Innovation Inc. invested $800,000 in Solx, Inc., a privately-held medical device company based in Westborough, MA. 

 

 

2

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

SPOTLIGHT INNOVATION INC.

 

Dated: December 7, 2016

By:

/s/ William Pim

 

William Pim, CFO

 

 

 

 

3